BR112023017728A2 - Anticorpos anti-nectin-4 e uso dos mesmos - Google Patents

Anticorpos anti-nectin-4 e uso dos mesmos

Info

Publication number
BR112023017728A2
BR112023017728A2 BR112023017728A BR112023017728A BR112023017728A2 BR 112023017728 A2 BR112023017728 A2 BR 112023017728A2 BR 112023017728 A BR112023017728 A BR 112023017728A BR 112023017728 A BR112023017728 A BR 112023017728A BR 112023017728 A2 BR112023017728 A2 BR 112023017728A2
Authority
BR
Brazil
Prior art keywords
nectin
antibodies
specificity
relates
present
Prior art date
Application number
BR112023017728A
Other languages
English (en)
Inventor
Daniel Olive
Florence Lhosppice
Jack Elands
Marc Lopez
Xavier Préville
Original Assignee
Centre Nat Rech Scient
Emergence Therapeutics Ag
Inst Nat Sante Rech Med
Inst Jean Paoli & Irene Calmettes
Univ Aix Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP21170941.5A external-priority patent/EP4066899A1/en
Priority claimed from EP21172723.5A external-priority patent/EP4086284A1/en
Application filed by Centre Nat Rech Scient, Emergence Therapeutics Ag, Inst Nat Sante Rech Med, Inst Jean Paoli & Irene Calmettes, Univ Aix Marseille filed Critical Centre Nat Rech Scient
Publication of BR112023017728A2 publication Critical patent/BR112023017728A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

anticorpos anti-nectin-4 e uso dos mesmos. a presente invenção refere-se a anticorpos tendo especificidade para nectin-4 e seu uso.
BR112023017728A 2021-03-31 2022-03-31 Anticorpos anti-nectin-4 e uso dos mesmos BR112023017728A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21166441 2021-03-31
EP21170941.5A EP4066899A1 (en) 2021-03-31 2021-04-28 Anti-nectin-4 antibody
EP21172723.5A EP4086284A1 (en) 2021-05-07 2021-05-07 Anti-nectin-4 antibody exatecan conjugates
EP21209332 2021-11-19
PCT/EP2022/058626 WO2022207822A1 (en) 2021-03-31 2022-03-31 Anti-nectin-4-antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112023017728A2 true BR112023017728A2 (pt) 2023-11-21

Family

ID=80999114

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112023017728A BR112023017728A2 (pt) 2021-03-31 2022-03-31 Anticorpos anti-nectin-4 e uso dos mesmos
BR112023019749A BR112023019749A2 (pt) 2021-03-31 2022-03-31 Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112023019749A BR112023019749A2 (pt) 2021-03-31 2022-03-31 Conjugados de exatecano anti-nectina-4, composição farmacêutica que os compreende e seus usos

Country Status (13)

Country Link
US (2) US20240173424A1 (pt)
EP (2) EP4314057A1 (pt)
JP (2) JP2024515536A (pt)
KR (2) KR20240028330A (pt)
AU (2) AU2022250867A1 (pt)
BR (2) BR112023017728A2 (pt)
CA (2) CA3212655A1 (pt)
CO (2) CO2023012821A2 (pt)
CR (2) CR20230469A (pt)
EC (2) ECSP23073625A (pt)
IL (2) IL305954A (pt)
PE (2) PE20240724A1 (pt)
WO (3) WO2022207828A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4285935A1 (en) * 2022-06-03 2023-12-06 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4309676A1 (en) * 2022-07-22 2024-01-24 Emergence Therapeutics AG Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4344707A1 (en) * 2022-09-29 2024-04-03 Emergence Therapeutics AG New anti-nectin-4 antibody drug conjugates

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311145A (en) 2010-09-29 2024-04-01 Seagen Inc Antibody drug conjugates (ADC) binding to 191P4D12 proteins
US10675357B2 (en) * 2015-09-09 2020-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale Antibodies having specificity to nectin-4 and uses thereof
PL3546448T3 (pl) * 2016-11-25 2022-09-05 Mabwell (shanghai) Bioscience Co., Ltd. Łącznik stanowiący dipodstawiony amid kwasu maleinowego dla koniugacji przeciwciało-lek oraz sposób jego wytwarzania i zastosowanie
CN110392697A (zh) * 2017-03-02 2019-10-29 国家医疗保健研究所 对nectin-4具有特异性的抗体及其用途
JP7381478B2 (ja) * 2017-10-23 2023-11-15 マブリンク ビオシオンス 単一分子量ポリサルコシンを含むリガンド－薬物－複合体
AU2020263959A1 (en) * 2019-04-24 2021-11-25 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP4041765A1 (en) * 2019-10-07 2022-08-17 Université d'Aix-Marseille Antibodies having specificity for nectin-4 and uses thereof
CN115052632A (zh) * 2020-01-15 2022-09-13 北京海步医药科技有限公司 靶向多肽-药物缀合物及其用途
WO2021151984A1 (en) * 2020-01-31 2021-08-05 Innate Pharma Treatment of cancer

Also Published As

Publication number Publication date
EP4262988A1 (en) 2023-10-25
PE20240725A1 (es) 2024-04-15
BR112023019749A2 (pt) 2024-01-23
CR20230470A (es) 2023-11-30
CO2023012821A2 (es) 2024-02-26
AU2022248735A1 (en) 2023-08-03
WO2022207828A1 (en) 2022-10-06
CO2023012828A2 (es) 2024-02-15
US20240173424A1 (en) 2024-05-30
WO2022207825A1 (en) 2022-10-06
US20240034791A1 (en) 2024-02-01
KR20240035378A (ko) 2024-03-15
EP4314057A1 (en) 2024-02-07
CA3212655A1 (en) 2022-10-06
ECSP23073625A (es) 2024-02-29
ECSP23073436A (es) 2024-02-29
IL305951A (en) 2023-11-01
JP2024520188A (ja) 2024-05-22
JP2024515536A (ja) 2024-04-10
CA3212651A1 (en) 2022-10-06
IL305954A (en) 2023-11-01
WO2022207822A1 (en) 2022-10-06
PE20240724A1 (es) 2024-04-15
KR20240028330A (ko) 2024-03-05
AU2022250867A1 (en) 2023-08-03
CR20230469A (es) 2023-11-30

Similar Documents

Publication Publication Date Title
BR112023017728A2 (pt) Anticorpos anti-nectin-4 e uso dos mesmos
BR112022017986A2 (pt) Anticorpos anticoronavírus e métodos de uso
BR112022003543A2 (pt) Inibidores de kras g12
BR112022018949A2 (pt) Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2)
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
CL2020000395A1 (es) Conjugados de pirrolobenzodiazepina.
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
EA202190542A1 (ru) Сконструированные биспецифические белки
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
PE20231376A1 (es) Anticuerpos contra el sars-cov-2 y metodos e seleccion y uso de los mismos
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
BR112022013878A2 (pt) Anticorpos que ligam integrina avb8 e utilizações dos mesmos
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
BR112019007760A2 (pt) anticorpos anti-edb e conjugados de anticorpo-fármaco
CL2022000052A1 (es) Anticuerpos de pre–direccionamiento y metodos de uso
CO2023015915A2 (es) Anticuerpos anti-ccr8
CL2023000216A1 (es) Anticuerpos anti-abeta
CL2022001545A1 (es) Composiciones y métodos para tratar y prevenir la influenza
CL2022000752A1 (es) Molécula de unión específica para lif y uso de la misma
BR112023001562A2 (pt) Uso de inibidores da via wnt/beta-catenina para bloquear a replicação de sars-cov-2 e outros vírus patogênicos
AR121530A1 (es) Anticuerpos anticoronavirus y métodos de uso
BR112021018611A2 (pt) Anticorpos tendo especificidade para btn2 e usos dos mesmos